-
Forward Look
What’s Next? Winter 2019/2020Treating prostate cancer with fewer side effects.
by Bradley Jones
-
Secure ConnectionsPatients find each other online and get support they say is unparalleled, but with openness comes concern about privacy.
by Kate Yandell
-
BRCA: Who Should Be Tested?Genetic testing for mutations in the BRCA1 and BRCA2 genes creates opportunities for cancer risk reduction. But 25 years after the mutations were discovered, some who could benefit from testing are still left out.
by Sue Rochman
-
Forward Look
Medicare to Cover CAR-T Cell TherapyHigh cost may still limit access.
by Nancy Averett
-
Forward Look
Targeted Treatments for TotsNew law mandates that cancer drugs get tested in kids in clinical trials.
by Sharon Tregaskis
-
Survivor Profile
Handle With CareBrain cancer survivor Lanette Veres sends cards and packages to others with the disease. She believes no one should face cancer alone.
by Lindsey Konkel
-
Cancer Patient Advocates Find Strength in NumbersPatient advocates have become a vital part of the San Antonio Breast Cancer Symposium. Opportunities for advocates continue to multiply.
by Marci A. Landsmann
-
Exploring Immunotherapy for Triple Negative Breast CancerFollowing the approval of the first immunotherapy for breast cancer by the U.S. Food and Drug Administration in March 2019, experts at the San Antonio Breast Cancer Symposium discussed avenues for further development.
by Marci A. Landsmann
-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast CancerStudies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
-
A Switch From Intravenous to Oral Chemo?Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
-
AACR IO: Revolutionizing Treatment through ImmunotherapyThe AACR’s immuno-oncology meeting brings together the leading experts in immunotherapy to accelerate progress in cancer science and medicine.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
